Dr. Bernard V. Fischbach, MD

Dr. Fischbach practices at DaVita Grapevine Dialysis in Grapevine, Texas.

Dr. Fischbach's NPI, 1225016819, was assigned on January 4, 2006. Dr. Fischbach graduated from Creighton University School of Medicine - Omaha in 1996. Dr. Fischbach holds Texas license L6378.

Dr. Fischbach's primary practice is DaVita Grapevine Dialysis, at 1651 W Northwest Highway Suite 100, Grapevine, TX 76051 in Tarrant County. The practice phone is (817) 251-0675.

Dr. Fischbach's primary practice is DaVita Grapevine Dialysis in Grapevine, Texas. Dr. Fischbach is also affiliated with Baylor University Medical Center. The medical group on file is Dallas Nephrology Associates. Dmand AI also links Dr. Fischbach to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fischbach practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Fischbach's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Fischbach is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Fischbach's licenses on file in 3 states: Texas, Kentucky and Tennessee.

Dmand AI lists chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Fischbach treats.

CMS data shows 1,435 Medicare services from Dr. Fischbach across 6 procedure codes in 2024, for 357 Medicare patients. Medicare paid $103,869 for them.

CMS counts 357 Medicare patients who saw Dr. Fischbach in 2024. The largest group is under 65, with 171 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 17% are also on Medicaid. Their average risk score is 4.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fischbach's median patient age at 59, with 41% women.

In 2024, Dr. Fischbach wrote 4,688 Medicare Part D claims for 391 patients. 92% of them were for generic drugs. CMS names the drug for 4,358 of them, across 59 drugs with 11 or more claims each, at $253,133 in total drug cost. In 2023, CMS named 3,917 claims across 51 drugs.

Dr. Fischbach accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fischbach as offering telehealth.

Dmand AI links 19 papers to Dr. Fischbach, published from 2016 to 2024. 2016 was the busiest year, with 2. The most frequent topics are Kidney Transplantation, COVID-19 and Glomerular Filtration Rate. Dr. Fischbach has published most often in Clin Nephrol. Dr. Fischbach's most frequent co-authors are Angelito F. Yango, MD, Goran B. G. Klintmalm, MD and Stevan A. Gonzalez, MD.

Dmand AI links Dr. Fischbach to 11 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Nephritis, Hereditary, Renal Insufficiency, Chronic and Renal Insufficiency. Biogen sponsors the most, 2. Open Payments lists research payments to Dr. Fischbach that name 1 trial.

CMS Open Payments shows 146 general payments to Dr. Fischbach from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Amgen Inc. paid the most, $367. It also lists 14 research payments totaling $124,430 from 2016 to 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Fischbach, most recently CMS Stage 1 2012 in 2012.

Dr. Fischbach graduated from Creighton University School of Medicine - Omaha in 1996.

Dr. Fischbach is in network with 23 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.